{"organizations": [], "uuid": "53a6446a89dbf1bed3cedff9b15ecc3e75372cd4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180124.html", "section_title": "Archive News &amp; Video for Wednesday, 24 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-intellipharmaceutics-provides-oper/brief-intellipharmaceutics-provides-operational-update-idUSASB0C23J", "country": "US", "domain_rank": 408, "title": "BRIEF-Intellipharmaceutics Provides Operational Update", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.107, "site_type": "news", "published": "2018-01-24T21:43:00.000+02:00", "replies_count": 0, "uuid": "53a6446a89dbf1bed3cedff9b15ecc3e75372cd4"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-intellipharmaceutics-provides-oper/brief-intellipharmaceutics-provides-operational-update-idUSASB0C23J", "ord_in_thread": 0, "title": "BRIEF-Intellipharmaceutics Provides Operational Update", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "china", "sentiment": "none"}], "organizations": [{"name": "reuters) - intellipharmaceutics international inc", "sentiment": "neutral"}, {"name": "fda", "sentiment": "none"}, {"name": "nal", "sentiment": "none"}, {"name": "mallinckrodt", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 24 (Reuters) - Intellipharmaceutics International Inc :\n* INTELLIPHARMACEUTICS PROVIDES OPERATIONAL UPDATE * INTELLIPHARMACEUTICS - COMMERCIALIZATION OPPORTUNITIES FOR CO‘S PRODUCT HAVE BEEN “CHALLENGING IN U.S. DUE TO EXTREMELY COMPETITIVE COST ENVIRONMENT”\n* INTELLIPHARMACEUTICS INTERNATIONAL INC - CONTINUES EFFORTS TO IDENTIFY OPPORTUNITIES OVERSEAS, INCLUDING IN CHINA\n* INTELLIPHARMACEUTICS - RECENTLY HELD DISCUSSIONS IN CHINA TOWARD ESTABLISHING A PARTNERSHIP, HAS NOT ENTERED INTO ANY SUCH ARRANGEMENTS YET\n* INTELLIPHARMACEUTICS - EVALUATING PARTNERS FOR PHASE III STUDIES OF REGABATIN XR, EXPECT TO BEGIN STUDIES IN H2 2018\n* INTELLIPHARMACEUTICS - CONTINUES TO WORK WITH MALLINCKRODT AND PAR TO GAIN TRACTION IN U.S. FOR GENERIC SEROQUEL XR AND GENERIC FOCALIN XR\n* INTELLIPHARMACEUTICS - ANTICIPATE THAT NDA FOR OXYCODONE ER ABUSE-DETERRENT PROGRAM WILL BE RESUBMITTED TO FDA IN LATE SUMMER 2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-24T21:43:00.000+02:00", "crawled": "2018-01-25T13:00:39.001+02:00", "highlightTitle": ""}